表皮生长因子受体突变和EML4-ALK融合基因均阳性的肺腺癌患者对吉非替尼和克唑替尼的长期反应 - Suppr

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

作者信息

Chiari Rita, Duranti Simona, Ludovini Vienna, Bellezza Guido, Pireddu Anjuta, Minotti Vincenzo, Bennati Chiara, Crinò Lucio

机构信息

Santa Maria della Misericordia Hospital, Perugia, Italy.

出版信息

J Clin Oncol. 2014 Mar 20;32(9):e30-2. doi: 10.1200/JCO.2012.47.7141. Epub 2014 Jan 13.

DOI:10.1200/JCO.2012.47.7141

PMID:24419120

Abstract

摘要

相似文献

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

J Clin Oncol. 2014 Mar 20;32(9):e30-2. doi: 10.1200/JCO.2012.47.7141. Epub 2014 Jan 13.

Clinical response to crizotinib retreatment after acquisition of drug resistance.

J Clin Oncol. 2013 Jul 1;31(19):e322-3. doi: 10.1200/JCO.2012.46.4305. Epub 2013 May 28.

New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.

Indian J Cancer. 2017 Jan-Mar;54(1):203-208. doi: 10.4103/ijc.IJC_72_17.

Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.

J Clin Oncol. 2015 Feb 10;33(5):e25-6. doi: 10.1200/JCO.2013.49.1985. Epub 2014 Mar 10.

Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.

Ann Oncol. 2017 Oct 1;28(10):2622-2624. doi: 10.1093/annonc/mdx324.

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.

Clin Lung Cancer. 2015 Mar;16(2):e5-9. doi: 10.1016/j.cllc.2014.11.001. Epub 2014 Nov 18.

A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.

Jpn J Clin Oncol. 2014 Oct;44(10):963-8. doi: 10.1093/jjco/hyu110. Epub 2014 Aug 28.

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.

J Transl Med. 2016 Oct 19;14(1):296. doi: 10.1186/s12967-016-1061-z.

A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene.

Lung Cancer. 2013 Aug;81(2):308-10. doi: 10.1016/j.lungcan.2013.05.003. Epub 2013 May 31.

[Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement].

Rev Mal Respir. 2017 May;34(5):576-580. doi: 10.1016/j.rmr.2016.08.002. Epub 2016 Sep 17.

引用本文的文献

Case report: Concomitant mutation and rearrangement in non-small cell lung cancer.

Front Pharmacol. 2023 Aug 29;14:1167959. doi: 10.3389/fphar.2023.1167959. eCollection 2023.

Heterocyclic chalcone ()-1-(2-hydroxy-3,4,6-trimethoxyphenyl)-3-(thiophen-2-yl) prop-2-en-1-one derived from a natural product with antinociceptive, anti-inflammatory, and hypoglycemic effect in adult zebrafish.

3 Biotech. 2023 Aug;13(8):276. doi: 10.1007/s13205-023-03696-8. Epub 2023 Jul 14.

A case of synchronous multiple primary lung adenocarcinomas harboring epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement successfully treated with combination of osimertinib and alectinib.

Respir Med Case Rep. 2021 Apr 13;33:101418. doi: 10.1016/j.rmcr.2021.101418. eCollection 2021.

Successful management of a lung cancer patient harbouring both mutation and fusion gene with disseminated intravascular coagulation.

Respir Med Case Rep. 2021 Mar 19;33:101393. doi: 10.1016/j.rmcr.2021.101393. eCollection 2021.

Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report.

Respir Med Case Rep. 2021 Mar 4;32:101378. doi: 10.1016/j.rmcr.2021.101378. eCollection 2021.

[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi. 2018 Sep 20;21(9):686-691. doi: 10.3779/j.issn.1009-3419.2018.09.07.

Synchronous Presence of , Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature.

World J Oncol. 2018 Apr;9(2):50-55. doi: 10.14740/wjon1090e. Epub 2018 May 1.

Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.

Intern Med. 2018 Aug 15;57(16):2377-2382. doi: 10.2169/internalmedicine.0383-17. Epub 2018 Mar 9.

Concomitant rearrangement and mutation in non-small cell lung cancer patients: a literature review of 100 cases.

Oncotarget. 2017 Apr 26;8(35):59889-59900. doi: 10.18632/oncotarget.17431. eCollection 2017 Aug 29.

Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis.

Sci Rep. 2017 Sep 8;7(1):10961. doi: 10.1038/s41598-017-11453-0.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献